243 related articles for article (PubMed ID: 34387082)
21. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
[TBL] [Abstract][Full Text] [Related]
22. The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.
Kelly K; Wang S; Boddu R; Liu Z; Moukha-Chafiq O; Augelli-Szafran C; West AB
Exp Neurol; 2018 Nov; 309():1-13. PubMed ID: 30048714
[TBL] [Abstract][Full Text] [Related]
23. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
[TBL] [Abstract][Full Text] [Related]
24. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
[TBL] [Abstract][Full Text] [Related]
25. Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.
Greshock TJ; Sanders JM; Drolet RE; Rajapakse HA; Chang RK; Kim B; Rada VL; Tiscia HE; Su H; Lai MT; Sur SM; Sanchez RI; Bilodeau MT; Renger JJ; Kern JT; McCauley JA
Bioorg Med Chem Lett; 2016 Jun; 26(11):2631-5. PubMed ID: 27106707
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
Scott JD; DeMong DE; Greshock TJ; Basu K; Dai X; Harris J; Hruza A; Li SW; Lin SI; Liu H; Macala MK; Hu Z; Mei H; Zhang H; Walsh P; Poirier M; Shi ZC; Xiao L; Agnihotri G; Baptista MA; Columbus J; Fell MJ; Hyde LA; Kuvelkar R; Lin Y; Mirescu C; Morrow JA; Yin Z; Zhang X; Zhou X; Chang RK; Embrey MW; Sanders JM; Tiscia HE; Drolet RE; Kern JT; Sur SM; Renger JJ; Bilodeau MT; Kennedy ME; Parker EM; Stamford AW; Nargund R; McCauley JA; Miller MW
J Med Chem; 2017 Apr; 60(7):2983-2992. PubMed ID: 28245354
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and Preliminary Evaluation of [
Chen Z; Shao T; Gao W; Fu H; Collier TL; Rong J; Deng X; Yu Q; Zhang X; Davenport AT; Daunais JB; Wey HY; Shao Y; Josephson L; Qiu WW; Liang S
ChemMedChem; 2019 Sep; 14(17):1580-1585. PubMed ID: 31365783
[TBL] [Abstract][Full Text] [Related]
28. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).
Williamson DS; Smith GP; Acheson-Dossang P; Bedford ST; Chell V; Chen IJ; Daechsel JCA; Daniels Z; David L; Dokurno P; Hentzer M; Herzig MC; Hubbard RE; Moore JD; Murray JB; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Thirstrup K; Wang Y; Christensen KV
J Med Chem; 2017 Nov; 60(21):8945-8962. PubMed ID: 29023112
[TBL] [Abstract][Full Text] [Related]
29. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
Chen J; Chen Y; Pu J
Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
[TBL] [Abstract][Full Text] [Related]
30. Small-Molecule Inhibitors of LRRK2.
Hatcher JM; Choi HG; Alessi DR; Gray NS
Adv Neurobiol; 2017; 14():241-264. PubMed ID: 28353288
[TBL] [Abstract][Full Text] [Related]
31. The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain.
Schmidt SH; Knape MJ; Boassa D; Mumdey N; Kornev AP; Ellisman MH; Taylor SS; Herberg FW
Proc Natl Acad Sci U S A; 2019 Jul; 116(30):14979-14988. PubMed ID: 31292254
[TBL] [Abstract][Full Text] [Related]
32. Allosteric inhibition of LRRK2, where are we now.
Soliman A; Cankara FN; Kortholt A
Biochem Soc Trans; 2020 Oct; 48(5):2185-2194. PubMed ID: 33079169
[TBL] [Abstract][Full Text] [Related]
33. A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
Leveridge M; Collier L; Edge C; Hardwicke P; Leavens B; Ratcliffe S; Rees M; Stasi LP; Nadin A; Reith AD
J Biomol Screen; 2016 Feb; 21(2):145-55. PubMed ID: 26403521
[TBL] [Abstract][Full Text] [Related]
34. Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease.
Zhao Y; Dzamko N
Drugs; 2019 Jul; 79(10):1037-1051. PubMed ID: 31161537
[TBL] [Abstract][Full Text] [Related]
35. Exploring natural compound, Panicutine as leucine-rich repeat kinase 2 inhibitor against Parkinson's disease: a structure-guided approach.
Majrashi TA; Wahab S; Almoyad MAA; Alkhathami AG; Alshahrani MY
J Biomol Struct Dyn; 2023 Oct; ():1-10. PubMed ID: 37837424
[TBL] [Abstract][Full Text] [Related]
36.
Wauters F; Cornelissen T; Imberechts D; Martin S; Koentjoro B; Sue C; Vangheluwe P; Vandenberghe W
Autophagy; 2020 Feb; 16(2):203-222. PubMed ID: 30945962
[TBL] [Abstract][Full Text] [Related]
37. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
Reichling LJ; Riddle SM
Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
[TBL] [Abstract][Full Text] [Related]
38. Unveiling the Selectivity Mechanism of Type-I LRRK2 Inhibitors by Computational Methods: Insights from Binding Thermodynamics and Kinetics Simulation.
Tan S; Wang J; Gao P; Xie G; Zhang Q; Liu H; Yao X
ACS Chem Neurosci; 2023 Sep; 14(18):3472-3486. PubMed ID: 37647597
[TBL] [Abstract][Full Text] [Related]
39. Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).
Galatsis P
Expert Opin Ther Pat; 2017 Jun; 27(6):667-676. PubMed ID: 28117607
[TBL] [Abstract][Full Text] [Related]
40. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
